Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon to Seek out Breast Cancer Biomarkers with MD Anderson

NEW YORK (GenomeWeb News) – Exiqon will seek microRNA biomarkers for breast cancer through a collaboration with the University of Texas MD Anderson Cancer Center, the company said today.
 
Under the collaboration, the Danish company Exiqon will use its miRCURY LNA locked nucleic acid nucleotide products to discover microRNA biomarkers for the Kleberg Center for Molecular Markers at the cancer center.
 
The collaboration is focused on identifying miRNA expression signatures associated with the relapse and progression of breast cancer, and Exiqon aims to develop and validate diagnostic tools that could be used to guide patient management.
 
Gordon Mills, who is director of the Kleberg Center, said the collaboration is part of the center’s efforts to unify DNA, RNA, and protein approaches in developing molecular markers that could help advance cancer treatment. 

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.